I-Mab (NASDAQ:NBP) Raised to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded I-Mab from “sell” to “hold.” With mixed analyst views, the stock has a consensus “Hold” rating and an average price target of $9.00.
• I-Mab shares opened at $2.00, versus a 52-week range of $1.46 to $6.79, and the company reported a quarterly loss of $0.16 per share.
• Brooklyn Investment Group recently purchased 12,715 shares of I-Mab, while institutional investors collectively own 38.38% of the clinical-stage biotechnology company.

I-Mab (NASDAQ:NBP - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

Several other equities research analysts also recently weighed in on the company. Weiss Ratings upgraded I-Mab from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, June 1st. HC Wainwright reissued a "buy" rating and set a $9.00 price objective on shares of I-Mab in a research report on Thursday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $9.00.

I-Mab Price Performance

Shares of NBP stock opened at $2.00 on Friday. The firm has a 50 day simple moving average of $1.78. The stock has a market cap of $231.30 million, a PE ratio of -5.56 and a beta of 1.47. I-Mab has a 52 week low of $1.46 and a 52 week high of $6.79.

I-Mab (NASDAQ:NBP - Get Free Report) last posted its quarterly earnings data on Thursday, August 20th. The company reported ($0.16) earnings per share for the quarter. On average, sell-side analysts predict that I-Mab will post -0.56 earnings per share for the current fiscal year.

Institutional Trading of I-Mab

An institutional investor recently bought a new stake in I-Mab stock. Brooklyn Investment Group bought a new stake in I-Mab (NASDAQ:NBP - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 12,715 shares of the company's stock, valued at approximately $51,000. 38.38% of the stock is owned by institutional investors.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source